Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Sell
27
ENTX Quote, Financials, Valuation and Earnings
Last price:
$1.76
Seasonality move
:
-18.52%
Day range:
$1.75 - $1.94
52-week range:
$1.50 - $3.22
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
625.02x
P/B ratio:
5.30x
Volume:
375.6K
Avg. volume:
91K
1-year change:
-10.48%
Market cap:
$80.7M
Revenue:
$181K
EPS (TTM):
-$0.24
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ENTX
Entera Bio Ltd.
|
-- | -- | -100% | -- | $10.00 |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $3.25 |
|
CGEN
Compugen Ltd.
|
$1.5M | -$0.09 | -7.77% | -9.81% | $6.25 |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-- | -$6.08 | -- | -206.85% | $399.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ENTX
Entera Bio Ltd.
|
$1.76 | $10.00 | $80.7M | -- | $0.00 | 0% | 625.02x |
|
CANF
Can-Fite BioPharma Ltd.
|
$0.24 | $3.25 | $3.8M | -- | $0.00 | 0% | 1.36x |
|
CGEN
Compugen Ltd.
|
$1.53 | $6.25 | $142.6M | 55.83x | $0.00 | 0% | 20.37x |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
PHGE
BiomX, Inc.
|
$2.07 | $399.00 | $3.2M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ENTX
Entera Bio Ltd.
|
1.37% | -0.380 | 0.24% | 10.57x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 0.899 | -- | -- |
|
CGEN
Compugen Ltd.
|
6.3% | 2.845 | 2.14% | 4.24x |
|
NSRX
Nasus Pharma
|
-- | 0.000 | -- | -- |
|
PHGE
BiomX, Inc.
|
38.57% | 0.072 | 20.14% | 1.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ENTX
Entera Bio Ltd.
|
-$8K | -$3.3M | -79.72% | -81.18% | -6102.38% | -$2.8M |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CGEN
Compugen Ltd.
|
$241K | -$7.9M | -49.12% | -51.8% | -417.4% | -- |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-$1.2M | -$8.5M | -116.24% | -160.84% | -- | -$7.2M |
Entera Bio Ltd. vs. Competitors
-
Which has Higher Returns ENTX or CANF?
Can-Fite BioPharma Ltd. has a net margin of -6111.91% compared to Entera Bio Ltd.'s net margin of --. Entera Bio Ltd.'s return on equity of -81.18% beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ENTXEntera Bio Ltd.-- -$0.07 $15.4M CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About ENTX or CANF?
Entera Bio Ltd. has a consensus price target of $10.00, signalling upside risk potential of 468.18%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $3.25 which suggests that it could grow by 1228.16%. Given that Can-Fite BioPharma Ltd. has higher upside potential than Entera Bio Ltd., analysts believe Can-Fite BioPharma Ltd. is more attractive than Entera Bio Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ENTXEntera Bio Ltd.0 0 0 CANFCan-Fite BioPharma Ltd.2 0 0 -
Is ENTX or CANF More Risky?
Entera Bio Ltd. has a beta of 1.706, which suggesting that the stock is 70.619% more volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 0.982, suggesting its less volatile than the S&P 500 by 1.756%.
-
Which is a Better Dividend Stock ENTX or CANF?
Entera Bio Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entera Bio Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENTX or CANF?
Entera Bio Ltd. quarterly revenues are --, which are larger than Can-Fite BioPharma Ltd. quarterly revenues of --. Entera Bio Ltd.'s net income of -$3.2M is higher than Can-Fite BioPharma Ltd.'s net income of --. Notably, Entera Bio Ltd.'s price-to-earnings ratio is -- while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entera Bio Ltd. is 625.02x versus 1.36x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENTXEntera Bio Ltd.625.02x -- -- -$3.2M CANFCan-Fite BioPharma Ltd.1.36x -- -- --
-
Which has Higher Returns ENTX or CGEN?
Compugen Ltd. has a net margin of -6111.91% compared to Entera Bio Ltd.'s net margin of -369.06%. Entera Bio Ltd.'s return on equity of -81.18% beat Compugen Ltd.'s return on equity of -51.8%.
Company Gross Margin Earnings Per Share Invested Capital ENTXEntera Bio Ltd.-- -$0.07 $15.4M CGENCompugen Ltd.12.75% -$0.07 $46.8M -
What do Analysts Say About ENTX or CGEN?
Entera Bio Ltd. has a consensus price target of $10.00, signalling upside risk potential of 468.18%. On the other hand Compugen Ltd. has an analysts' consensus of $6.25 which suggests that it could grow by 308.5%. Given that Entera Bio Ltd. has higher upside potential than Compugen Ltd., analysts believe Entera Bio Ltd. is more attractive than Compugen Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ENTXEntera Bio Ltd.0 0 0 CGENCompugen Ltd.4 0 0 -
Is ENTX or CGEN More Risky?
Entera Bio Ltd. has a beta of 1.706, which suggesting that the stock is 70.619% more volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.823%.
-
Which is a Better Dividend Stock ENTX or CGEN?
Entera Bio Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entera Bio Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENTX or CGEN?
Entera Bio Ltd. quarterly revenues are --, which are smaller than Compugen Ltd. quarterly revenues of $1.9M. Entera Bio Ltd.'s net income of -$3.2M is higher than Compugen Ltd.'s net income of -$7M. Notably, Entera Bio Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entera Bio Ltd. is 625.02x versus 20.37x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENTXEntera Bio Ltd.625.02x -- -- -$3.2M CGENCompugen Ltd.20.37x 55.83x $1.9M -$7M
-
Which has Higher Returns ENTX or NSRX?
Nasus Pharma has a net margin of -6111.91% compared to Entera Bio Ltd.'s net margin of --. Entera Bio Ltd.'s return on equity of -81.18% beat Nasus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ENTXEntera Bio Ltd.-- -$0.07 $15.4M NSRXNasus Pharma-- -- -- -
What do Analysts Say About ENTX or NSRX?
Entera Bio Ltd. has a consensus price target of $10.00, signalling upside risk potential of 468.18%. On the other hand Nasus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Entera Bio Ltd. has higher upside potential than Nasus Pharma, analysts believe Entera Bio Ltd. is more attractive than Nasus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings ENTXEntera Bio Ltd.0 0 0 NSRXNasus Pharma0 0 0 -
Is ENTX or NSRX More Risky?
Entera Bio Ltd. has a beta of 1.706, which suggesting that the stock is 70.619% more volatile than S&P 500. In comparison Nasus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ENTX or NSRX?
Entera Bio Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nasus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entera Bio Ltd. pays -- of its earnings as a dividend. Nasus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENTX or NSRX?
Entera Bio Ltd. quarterly revenues are --, which are larger than Nasus Pharma quarterly revenues of --. Entera Bio Ltd.'s net income of -$3.2M is higher than Nasus Pharma's net income of --. Notably, Entera Bio Ltd.'s price-to-earnings ratio is -- while Nasus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entera Bio Ltd. is 625.02x versus -- for Nasus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENTXEntera Bio Ltd.625.02x -- -- -$3.2M NSRXNasus Pharma-- -- -- --
-
Which has Higher Returns ENTX or PHGE?
BiomX, Inc. has a net margin of -6111.91% compared to Entera Bio Ltd.'s net margin of --. Entera Bio Ltd.'s return on equity of -81.18% beat BiomX, Inc.'s return on equity of -160.84%.
Company Gross Margin Earnings Per Share Invested Capital ENTXEntera Bio Ltd.-- -$0.07 $15.4M PHGEBiomX, Inc.-- -$5.55 $17.1M -
What do Analysts Say About ENTX or PHGE?
Entera Bio Ltd. has a consensus price target of $10.00, signalling upside risk potential of 468.18%. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 19175.36%. Given that BiomX, Inc. has higher upside potential than Entera Bio Ltd., analysts believe BiomX, Inc. is more attractive than Entera Bio Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ENTXEntera Bio Ltd.0 0 0 PHGEBiomX, Inc.1 0 0 -
Is ENTX or PHGE More Risky?
Entera Bio Ltd. has a beta of 1.706, which suggesting that the stock is 70.619% more volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.
-
Which is a Better Dividend Stock ENTX or PHGE?
Entera Bio Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entera Bio Ltd. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENTX or PHGE?
Entera Bio Ltd. quarterly revenues are --, which are smaller than BiomX, Inc. quarterly revenues of --. Entera Bio Ltd.'s net income of -$3.2M is higher than BiomX, Inc.'s net income of -$9.2M. Notably, Entera Bio Ltd.'s price-to-earnings ratio is -- while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entera Bio Ltd. is 625.02x versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENTXEntera Bio Ltd.625.02x -- -- -$3.2M PHGEBiomX, Inc.-- -- -- -$9.2M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 4.13% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is up 12.87% over the past day.
